Vanguard Personalized Indexing Management’s Quince Therapeutics QNCX Stock Holding History

Vanguard Personalized Indexing Management’s Portfolio QNCX Stock Details QNCX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$13.5K	Buy	+663	New	+$133K	﹤0.01%	2140

Other funds holding QNCX

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Shay Capital New York $1.2B AUM 37.47% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

IEQ Capital Foster City, California $21.5B AUM 75.26% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Vanguard Personalized Indexing Management's QNCX Position: Q1 2026 in Review

Vanguard Personalized Indexing Management opened a new position in Quince Therapeutics (QNCX) in Q1 2026: 663 shares worth $13.5K. The stake represents ﹤0.01% of the portfolio and ranks #2140 among its holdings.

43 funds tracked by Wall St. Rank hold QNCX as of Q1 2026.

Vanguard Personalized Indexing Management held 663 shares of Quince Therapeutics worth $13.5K as of Q1 2026.
Quince Therapeutics was a new Vanguard Personalized Indexing Management position in Q1 2026.
Quince Therapeutics made up ﹤0.01% of Vanguard Personalized Indexing Management's portfolio in Q1 2026, its #2140 holding.
43 funds tracked by Wall St. Rank held Quince Therapeutics as of Q1 2026.

Based on Vanguard Personalized Indexing Management's 13F filing for Q1 2026, filed 14 May 2026.